These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38850661)

  • 1. Cuproptosis in cancers: Function and implications from bench to bedside.
    Huang XY; Shen JY; Huang K; Wang L; Sethi G; Ma Z
    Biomed Pharmacother; 2024 Jul; 176():116874. PubMed ID: 38850661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance.
    Wang Y; Chen Y; Zhang J; Yang Y; Fleishman JS; Wang Y; Wang J; Chen J; Li Y; Wang H
    Drug Resist Updat; 2024 Jan; 72():101018. PubMed ID: 37979442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cuproptosis: unveiling a new frontier in cancer biology and therapeutics.
    Feng Y; Yang Z; Wang J; Zhao H
    Cell Commun Signal; 2024 May; 22(1):249. PubMed ID: 38693584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives.
    Zhang C; Huang T; Li L
    J Hematol Oncol; 2024 Aug; 17(1):68. PubMed ID: 39152464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis and its application in different cancers: an overview.
    Xu L; Liu K; Wang F; Su Y
    Mol Cell Biochem; 2023 Dec; 478(12):2683-2693. PubMed ID: 36914880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics revealed the crosstalk between copper stress and cuproptosis, and explored the feasibility of curcumin as anticancer copper ionophore.
    Yang Y; Liang S; Geng H; Xiong M; Li M; Su Q; Jia F; Zhao Y; Wang K; Jiang J; Qin S; Li X
    Free Radic Biol Med; 2022 Nov; 193(Pt 2):638-647. PubMed ID: 36395954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis: mechanisms and links with cancers.
    Xie J; Yang Y; Gao Y; He J
    Mol Cancer; 2023 Mar; 22(1):46. PubMed ID: 36882769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory roles of copper metabolism and cuproptosis in human cancers.
    Wang Z; Jin D; Zhou S; Dong N; Ji Y; An P; Wang J; Luo Y; Luo J
    Front Oncol; 2023; 13():1123420. PubMed ID: 37035162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review.
    Abdolmaleki S; Aliabadi A; Khaksar S
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):213. PubMed ID: 38662225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The crosstalk between copper-induced oxidative stress and cuproptosis: a novel potential anticancer paradigm.
    Vo TTT; Peng TY; Nguyen TH; Bui TNH; Wang CS; Lee WJ; Chen YL; Wu YC; Lee IT
    Cell Commun Signal; 2024 Jul; 22(1):353. PubMed ID: 38970072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferroptosis and cuproptosis: Metal-dependent cell death pathways activated in response to classical chemotherapy - Significance for cancer treatment?
    Kciuk M; Gielecińska A; Kałuzińska-Kołat Ż; Yahya EB; Kontek R
    Biochim Biophys Acta Rev Cancer; 2024 Jul; 1879(4):189124. PubMed ID: 38801962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug.
    Gao J; Wu X; Huang S; Zhao Z; He W; Song M
    Redox Biol; 2023 Nov; 67():102891. PubMed ID: 37734229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copper homeostasis and cuproptosis in tumor pathogenesis and therapeutic strategies.
    Bian C; Zheng Z; Su J; Chang S; Yu H; Bao J; Xin Y; Jiang X
    Front Pharmacol; 2023; 14():1271613. PubMed ID: 37767404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copper homeostasis and cuproptosis in cancer immunity and therapy.
    Liu WQ; Lin WR; Yan L; Xu WH; Yang J
    Immunol Rev; 2024 Jan; 321(1):211-227. PubMed ID: 37715546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cuproptosis: Unraveling the Mechanisms of Copper-Induced Cell Death and Its Implication in Cancer Therapy.
    Springer C; Humayun D; Skouta R
    Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.
    Zheng P; Zhou C; Lu L; Liu B; Ding Y
    J Exp Clin Cancer Res; 2022 Sep; 41(1):271. PubMed ID: 36089608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep learning enables the discovery of a novel cuproptosis-inducing molecule for the inhibition of hepatocellular carcinoma.
    Yang F; Jia L; Zhou HC; Huang JN; Hou MY; Liu FT; Prabhu N; Li ZJ; Yang CB; Zou C; Nordlund P; Wang JG; Dai LY
    Acta Pharmacol Sin; 2024 Feb; 45(2):391-404. PubMed ID: 37803139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuproptosis in lung cancer: therapeutic options and prognostic models.
    Jawed R; Bhatti H
    Apoptosis; 2024 Oct; 29(9-10):1393-1398. PubMed ID: 38735011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copper homeostasis and cuproptosis in health and disease.
    Chen L; Min J; Wang F
    Signal Transduct Target Ther; 2022 Nov; 7(1):378. PubMed ID: 36414625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cuproptosis in cancer: biological implications and therapeutic opportunities.
    Li L; Zhou H; Zhang C
    Cell Mol Biol Lett; 2024 Jun; 29(1):91. PubMed ID: 38918694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.